论文部分内容阅读
目的分析乙型肝炎肝硬化失代偿期、原发性肝癌(Hepatocellular Carcinoma,HCC)患者抗病毒治疗知晓现状。方法应用回顾性分析及电话随访的方法对113例乙型肝炎肝硬化失代偿期及HCC患者的一般资料及抗病毒治疗的病史资料进行收集与分析。结果 113例患者中以以40~50岁男性居多,占39.8%。乙肝肝硬化失代偿期患者中曾经进行抗病毒治疗的患者38例(33.6%);未进行抗病毒治疗的患者75例(66.4%)。23例HCC患者中未进行抗病毒治疗者21例(91.3%),进行抗病毒治疗的2例(8.7%)。结论乙型肝炎肝硬化患者中未及时进行抗病毒治疗是发展成为慢性HBV感染所致终末期肝病的主要原因。积极向慢性HBV感染者,尤其是乙型肝炎肝硬化患者进行规范治疗的健康宣教对预防肝硬化、肝癌的发生有着重要意义。
Objective To analyze the status quo of antiviral therapy in patients with decompensated hepatitis B and liver cirrhosis (Hepatocellular Carcinoma, HCC). Methods A retrospective analysis and telephone follow-up method were used to collect and analyze 113 cases of hepatitis B cirrhosis decompensated and HCC patients’ general information and anti-virus treatment history data. Results Among the 113 patients, the majority of men aged 40-50 years were 39.8%. Thirty-eight patients (33.6%) had anti-retroviral treatment and 75 patients (66.4%) did not receive anti-retroviral therapy. Twenty-one patients (91.3%) did not undergo antiviral therapy in 23 patients with HCC, and two patients (8.7%) received antiviral therapy. Conclusion The lack of timely antiviral treatment in patients with hepatitis B cirrhosis is the main reason for the development of end-stage liver disease caused by chronic HBV infection. Actively propagating health education to patients with chronic HBV infection, especially patients with hepatitis B cirrhosis, is of great significance in preventing the occurrence of liver cirrhosis and liver cancer.